#novo-nordisk

[ follow ]
#ozempic
Wearables
from24/7 Wall St.
3 months ago

Novo Nordisk (NYSE: NVO) Stock Price Prediction and Forecast 2025-2030 (April 2025)

Ozempic's explosive sales growth reflects its successful transition from a diabetes treatment to a leading weight loss drug.
more#ozempic
#wegovy
NYC startup
fromwww.nytimes.com
5 months ago

Weight Loss Drug Will Be Offered for $499 a Month for Some Patients

Novo Nordisk reduces Wegovy's price to $499 for cash-paying patients, but government-insured patients still face high costs.
NYC startup
fromwww.nytimes.com
5 months ago

Weight Loss Drug Will Be Offered for $499 a Month for Some Patients

Novo Nordisk reduces Wegovy's price to $499 for cash-paying patients, but government-insured patients still face high costs.
more#wegovy
from24/7 Wall St.
1 day ago

There Is Only 1 GLP-1 Stock to Buy In 2025

Ozempic's approval in 2017 transformed obesity treatment from lifestyle changes to drug-based interventions, utilizing GLP-1 to effectively regulate appetite and manage glucose.
Health
from24/7 Wall St.
3 weeks ago

3 Dividend Growth Stocks to Turn $10,000 Into $50,000 by 2035

High dividend growth stocks can potentially deliver triple-digit gains in the long run.
#obesity
more#obesity
from24/7 Wall St.
1 month ago

7 Killer European Stocks To Buy In July

The article highlights key European stocks, including Spotify and Novo Nordisk, that investors should consider for portfolio growth amid global market uncertainties.
E-Commerce
fromInsideHook
1 month ago

Compounding Breaks Up Novo Nordisk-Hims & Hers Partnership

Compounded alternatives to GLP-1 drugs raise safety concerns and regulatory scrutiny.
Intellectual property law
fromAbove the Law
2 months ago

Patenting Privation (Part III): Empowering Revenge - Above the Law

The FDA's lifting of the shortage declaration has curtailed bulk sales of competing diabetes medications, impacting telehealth revenues significantly.
Startup companies
fromFast Company
2 months ago

Novo Nordisk announces CEO transition as share price slips

Novo Nordisk's CEO Lars Fruergaard Jorgensen is stepping down amid market challenges despite leading the company through significant growth in the weight-loss drug sector.
fromwww.aljazeera.com
2 months ago

In surprise move Wegovy-maker Novo Nordisk ousts CEO amid sagging sales

Days earlier, Novo Nordisk cut its sales and profit forecast for the first time since the launch of Wegovy four years ago. Wegovy-maker Novo Nordisk has pushed out CEO Lars Fruergaard Jorgensen over concerns the company is losing its first-mover advantage in the highly competitive obesity drug market.
Europe news
fromCbsnews
2 months ago

Novo Nordisk CEO Lars Jorgensen, who led company into weight loss drugs, to step down

Novo Nordisk's board and CEO Lars Fruergaard Jorgensen have agreed his departure is necessary due to recent market challenges and a significant decline in share price.
NYC startup
#weight-loss-drugs
fromFast Company
3 months ago
Startup companies

Novo Nordisk posts strong Q1 as weight-loss revolution claims another victim: WeightWatchers

Novo Nordisk's market outlook improves with FDA's ban on GLP-1 drug copycats.
Despite profit forecasts lowering, investor sentiment towards Novo Nordisk remains optimistic.
Startup companies
fromFast Company
3 months ago

Novo Nordisk posts strong Q1 as weight-loss revolution claims another victim: WeightWatchers

Novo Nordisk's market outlook improves with FDA's ban on GLP-1 drug copycats.
Despite profit forecasts lowering, investor sentiment towards Novo Nordisk remains optimistic.
more#weight-loss-drugs
NYC startup
fromFuturism
3 months ago

Novo Nordisk Is Getting Absolutely Destroyed

Novo Nordisk's stock has fallen sharply after Eli Lilly announced effective trial results for an oral weight-loss pill.
#sap
more#sap
Medicine
fromFast Company
7 months ago

Novo Nordisk stock price takes a tumble after the Wegovy maker's next-generation weight-loss drug underwhelms

CagriSema failed to meet weight loss expectations in trials, causing significant stock decline for Novo Nordisk.
Miscellaneous
fromFuturism
8 months ago

Dr. Oz Will Have a Fascinating Conflict of Interest Running Medicare: Ozempic

Mehmet Oz's potential role in leading Medicare raises concerns due to his past connections with Novo Nordisk, makers of Ozempic.
fromFortune
9 months ago

Novo's main Ozempic plant cited for quality lapses by FDA

Novo Nordisk's Kalundborg plant, crucial for producing Ozempic and Wegovy, faced FDA scrutiny over microbial control, complicating efforts to meet rising drug demand.
Medicine
[ Load more ]